Aurinia Pharmaceuticals Inc. (AUPH) belongs to the “” sector with an industry focus on “”, with Dr. Richard M. Glickman L.L.D. (Hon) as Founder, Chairman and Chief Exec. Officer.
The company has been one of the biggest innovators in “” employing approximately 20 full time employees.
- The stock added in the prior trading session by 1.99%, closing at the stock price of $7.68.
- Currently, the market capitalization of Aurinia Pharmaceuticals Inc. (AUPH) is 627.97 Million.
- AUPH has a 1-year high price of $ 10.54 and 1-year low price of $1.74.
- The number of shares currently held by investors is 52.81 Million.
- The number of shares traded in the last trading session was 3.92 Million.
Currently the shares of Aurinia Pharmaceuticals Inc. (AUPH) has a trading volume of 3.92 Million shares, with an average trading volume of 2830 shares – with shares dropping to a 52 week low of $1.74, and the company’s shares hitting a 52 week high of $ 10.54.
Looking at the current price of the stock and the 52 week high and low, it suggests that the stock is likely to go Down in the future.
Earnings per share (EPS) breaks down the profitability of the company on a single share basis, and for Aurinia Pharmaceuticals Inc. the EPS stands at -0.22 for the previous quarter, while the analysts predicted the EPS of the stock to be -0.12, suggesting the stock fell short of the analysts’ expectations.
Another critical number in evaluating a stock is P/E or the price to earnings ratio.
The TTM operating margin is 0%. The return on invested capital at 0%, which is good, compared to its peers.
The Free Cash Flow or FCF margin is 0%, which means that the business has healthy reserve funds for contingencies that may arise.
Stock is currently moving with a positive distance from the 200 day simple moving average of approximately 90.28%, and has a solid year to date (YTD) performance of 265.71% which means the stock is constantly adding to its value from the previous fiscal year end price.
The target price for Aurinia Pharmaceuticals Inc. (AUPH) is $11.75/share according to the consensus of analysts working on the stock, with an expected EPS of $-0.12/share for the current quarter.